125 related articles for article (PubMed ID: 32910125)
21. A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity.
Tan J; Li C; Wang Q; Li S; Chen S; Zhang J; Wang PC; Ren L; Liang XJ
Mol Pharm; 2018 Apr; 15(4):1724-1728. PubMed ID: 29522683
[TBL] [Abstract][Full Text] [Related]
22. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
23. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
24. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
25. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant Pt
Norman DJ; Gambardella A; Mount AR; Murray AF; Bradley M
Angew Chem Int Ed Engl; 2019 Oct; 58(40):14189-14192. PubMed ID: 31397963
[TBL] [Abstract][Full Text] [Related]
26. Engineered flavoproteins as bioorthogonal photo-triggers for the activation of metal-based anticancer prodrugs.
Mazzei LF; Gurruchaga-Pereda J; Martínez Á; Martínez JC; Salassa L; Cortajarena AL
Chem Commun (Camb); 2023 Apr; 59(32):4754-4757. PubMed ID: 36974961
[TBL] [Abstract][Full Text] [Related]
27. Flavin-Conjugated Pt(IV) Anticancer Agents.
Sánchez-Camacho J; Infante-Tadeo S; Carrasco AC; Scoditti S; Martínez Á; Barroso-Bujans F; Sicilia E; Pizarro AM; Salassa L
Inorg Chem; 2023 Apr; 62(14):5644-5651. PubMed ID: 36990656
[TBL] [Abstract][Full Text] [Related]
28. Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.
Chin CF; Tian Q; Setyawati MI; Fang W; Tan ES; Leong DT; Ang WH
J Med Chem; 2012 Sep; 55(17):7571-82. PubMed ID: 22876932
[TBL] [Abstract][Full Text] [Related]
29. Platinum(IV) prodrug conjugated Pd@Au nanoplates for chemotherapy and photothermal therapy.
Shi S; Chen X; Wei J; Huang Y; Weng J; Zheng N
Nanoscale; 2016 Mar; 8(10):5706-13. PubMed ID: 26900670
[TBL] [Abstract][Full Text] [Related]
30. Studies on the photoactivation of two cytotoxic trans,trans,trans-diazidodiaminodihydroxo-Pt(IV) complexes.
Westendorf AF; Bodtke A; Bednarski PJ
Dalton Trans; 2011 May; 40(19):5342-51. PubMed ID: 21461431
[TBL] [Abstract][Full Text] [Related]
31. Synergic highly effective photothermal-chemotherapy with platinum prodrug linked melanin-like nanoparticles.
Zhang C; Zhao X; Guo H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):356-363. PubMed ID: 29607699
[TBL] [Abstract][Full Text] [Related]
32. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
33. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
34. Immobilizing CdS quantum dots and dendritic Pt nanocrystals on thiolated graphene nanosheets toward highly efficient photocatalytic H2 evolution.
Fang Z; Wang Y; Song J; Sun Y; Zhou J; Xu R; Duan H
Nanoscale; 2013 Oct; 5(20):9830-8. PubMed ID: 23970033
[TBL] [Abstract][Full Text] [Related]
35. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
[TBL] [Abstract][Full Text] [Related]
36. Development and current status of unconventional platinum anticancer complexes.
Abu-Surrah AS
Mini Rev Med Chem; 2007 Feb; 7(2):203-11. PubMed ID: 17305594
[TBL] [Abstract][Full Text] [Related]
37. Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
Ding S; Pickard AJ; Kucera GL; Bierbach U
Chemistry; 2014 Dec; 20(49):16164-73. PubMed ID: 25303639
[TBL] [Abstract][Full Text] [Related]
38. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.
Dhar S; Daniel WL; Giljohann DA; Mirkin CA; Lippard SJ
J Am Chem Soc; 2009 Oct; 131(41):14652-3. PubMed ID: 19778015
[TBL] [Abstract][Full Text] [Related]
39. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
[TBL] [Abstract][Full Text] [Related]
40. Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.
Dabbish E; Ponte F; Russo N; Sicilia E
Inorg Chem; 2019 Mar; 58(6):3851-3860. PubMed ID: 30843385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
